Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection
View ORCID ProfileAriel Israel, Yotam Shenhar, Ilan Green, View ORCID ProfileEugene Merzon, Avivit Golan-Cohen, View ORCID ProfileAlejandro A Schäffer, View ORCID ProfileEytan Ruppin, View ORCID ProfileShlomo Vinker, View ORCID ProfileEli Magen
doi: https://doi.org/10.1101/2021.08.19.21262111
Ariel Israel
1Leumit Research Institute & Department of Family Medicine, Leumit Health Services, Israel
MD, PhDYotam Shenhar
1Leumit Research Institute & Department of Family Medicine, Leumit Health Services, Israel
MDIlan Green
1Leumit Research Institute & Department of Family Medicine, Leumit Health Services, Israel
2Department of Family Medicine, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
MDEugene Merzon
1Leumit Research Institute & Department of Family Medicine, Leumit Health Services, Israel
2Department of Family Medicine, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
MDAvivit Golan-Cohen
1Leumit Research Institute & Department of Family Medicine, Leumit Health Services, Israel
2Department of Family Medicine, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
MDAlejandro A Schäffer
3Cancer Data Science Laboratory, National Cancer Institute, Bethesda, MD USA
PhDEytan Ruppin
3Cancer Data Science Laboratory, National Cancer Institute, Bethesda, MD USA
MD, PhDShlomo Vinker
1Leumit Research Institute & Department of Family Medicine, Leumit Health Services, Israel
2Department of Family Medicine, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
MD, MHAEli Magen
1Leumit Research Institute & Department of Family Medicine, Leumit Health Services, Israel
4Medicine C Department, Clinical Immunology and Allergy Division, Barzilai University Medical Center, Ben Gurion University of the Negev, Israel
MDData Availability
Data were obtained from patients' electronic health records, and IRB approval restrains its use to researchers inside Leumit Health Services.
Posted August 22, 2021.
Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection
Ariel Israel, Yotam Shenhar, Ilan Green, Eugene Merzon, Avivit Golan-Cohen, Alejandro A Schäffer, Eytan Ruppin, Shlomo Vinker, Eli Magen
medRxiv 2021.08.19.21262111; doi: https://doi.org/10.1101/2021.08.19.21262111
Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection
Ariel Israel, Yotam Shenhar, Ilan Green, Eugene Merzon, Avivit Golan-Cohen, Alejandro A Schäffer, Eytan Ruppin, Shlomo Vinker, Eli Magen
medRxiv 2021.08.19.21262111; doi: https://doi.org/10.1101/2021.08.19.21262111
Subject Area
Subject Areas
- Addiction Medicine (372)
- Allergy and Immunology (690)
- Anesthesia (184)
- Cardiovascular Medicine (2756)
- Dermatology (235)
- Emergency Medicine (414)
- Epidemiology (12404)
- Forensic Medicine (10)
- Gastroenterology (784)
- Genetic and Genomic Medicine (4264)
- Geriatric Medicine (396)
- Health Economics (700)
- Health Informatics (2760)
- Health Policy (1020)
- Hematology (370)
- HIV/AIDS (880)
- Medical Education (404)
- Medical Ethics (112)
- Nephrology (454)
- Neurology (4045)
- Nursing (216)
- Nutrition (600)
- Oncology (2132)
- Ophthalmology (606)
- Orthopedics (251)
- Otolaryngology (313)
- Pain Medicine (256)
- Palliative Medicine (77)
- Pathology (478)
- Pediatrics (1149)
- Primary Care Research (470)
- Public and Global Health (6659)
- Radiology and Imaging (1446)
- Respiratory Medicine (886)
- Rheumatology (421)
- Sports Medicine (353)
- Surgery (465)
- Toxicology (57)
- Transplantation (192)
- Urology (171)